{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T15:28:37Z","timestamp":1786548517906,"version":"build-2736575974"},"reference-count":99,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The rapid evolution of antibody-based biologics is transforming the management of chronic conditions and driving innovation in drug-delivery devices and container closure systems (CCS). Combination therapy enabled through coformulation or coadministration offers the potential for synergistic outcomes that are not achievable with single-drug products. This review examines development pathways and emerging strategies for delivery devices and CCS that support antibody-biologic coformulations and coadministration, from clinical trials through commercialization. We evaluate established technologies with an emphasis on design and delivery mechanisms, and on key technical considerations, including compatibility with dual-molecule formulations, protein\u2013protein interactions, sterilization approaches, container closure integrity, and human factors in CCS and device design. We also highlight emerging technologies and future opportunities for advancement. Overall, this review provides insights into the challenges and innovations shaping CCS and delivery systems for co-formulated or co-administered antibody biologics.<\/jats:p>","DOI":"10.1093\/abt\/tbag034","type":"journal-article","created":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T11:39:36Z","timestamp":1781955576000},"page":"437-448","source":"Crossref","is-referenced-by-count":0,"title":["Delivery devices and container closure systems for co-formulated and co-administered biologics"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-5417-4278","authenticated-orcid":false,"given":"Ming","family":"Zhou","sequence":"first","affiliation":[{"name":"Delivery Device and Connected Solutions, Lilly Research Laboratories, Eli Lilly and Company , Indianapolis, IN 46225 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Duffy","sequence":"additional","affiliation":[{"name":"Delivery Device and Connected Solutions, Lilly Research Laboratories, Eli Lilly and Company , Indianapolis, IN 46225 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Mitchener","sequence":"additional","affiliation":[{"name":"Delivery Device and Connected Solutions, Lilly Research Laboratories, Eli Lilly and Company , Indianapolis, IN 46225 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galen Huaiqiu","family":"Shi","sequence":"additional","affiliation":[{"name":"Delivery Device and Connected Solutions, Lilly Research Laboratories, Eli Lilly and Company , Indianapolis, IN 46225 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Collins","sequence":"additional","affiliation":[{"name":"Delivery Device and Connected Solutions, Lilly Research Laboratories, Eli Lilly and Company , Indianapolis, IN 46225 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"2026081210264188900_ref1","author":"US FDA"},{"key":"2026081210264188900_ref2","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1126\/science.adn4128","article-title":"The benefits of GLP-1 drugs beyond obesity","volume":"385","author":"Drucker","year":"2024","journal-title":"Science"},{"key":"2026081210264188900_ref3","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"2026081210264188900_ref4","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1007\/s10555-024-10192-9","article-title":"The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer","volume":"43","author":"Ibrahim","year":"2024","journal-title":"Cancer Metastasis Rev"},{"key":"2026081210264188900_ref5","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med"},{"key":"2026081210264188900_ref6","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","article-title":"Tirzepatide for the treatment of obstructive sleep apnea and obesity","volume":"391","author":"Malhotra","year":"2024","journal-title":"N Engl J Med"},{"key":"2026081210264188900_ref7","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in non-alcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"key":"2026081210264188900_ref8","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"2026081210264188900_ref9","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12985-025-02645-6","article-title":"Revolutionizing immunization: a comprehensive review of mRNA vaccine technology and applications","volume":"22","author":"Leong","year":"2025","journal-title":"Virol J"},{"key":"2026081210264188900_ref10","doi-asserted-by":"publisher","first-page":"151","DOI":"10.58347\/tml.2024.1711c","article-title":"COVID-19 update: new Pfizer and Moderna vaccine formulations for 2024\u20132025","volume":"66","year":"2024","journal-title":"Med Lett Drugs Ther"},{"key":"2026081210264188900_ref11","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines\u2014a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"2026081210264188900_ref12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3389\/fimmu.2022.1029069","article-title":"mRNA vaccines for cancer immunotherapy","volume":"13","author":"Vishweshwaraiah","year":"2022","journal-title":"Front Immunol"},{"key":"2026081210264188900_ref13","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1136\/ard-2024-225492","article-title":"What rheumatologists need to know about mRNA vaccines: current status and future of mRNA vaccines in autoimmune inflammatory rheumatic diseases","volume":"83","author":"Park","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2026081210264188900_ref14","doi-asserted-by":"publisher","first-page":"886","DOI":"10.4049\/immunohorizons.2300102","article-title":"Recent advances in the development of monoclonal antibodies and next-generation antibodies","volume":"7","author":"Singh","year":"2023","journal-title":"ImmunoHorizons."},{"key":"2026081210264188900_ref15","first-page":"181","article-title":"A comprehensive review of the mechanisms and clinical development of monoclonal antibodies in cancer therapy","volume":"24","author":"Eker","year":"2024","journal-title":"Cell Biol Transl Med"},{"key":"2026081210264188900_ref16","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/j.drudis.2017.05.011","article-title":"Advances in antibody\u2013drug conjugates: a new era of targeted cancer therapy","volume":"22","author":"Sau","year":"2017","journal-title":"Drug Discov Today"},{"key":"2026081210264188900_ref17","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13045-015-0227-0","article-title":"Bispecific antibodies and their applications","volume":"8","author":"Fan","year":"2015","journal-title":"J Hematol Oncol"},{"key":"2026081210264188900_ref18","volume-title":"Bispecific Antibodies: An Area of Research and Clinical Applications","author":"US FDA","year":"2024"},{"key":"2026081210264188900_ref19","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.trecan.2024.07.002","article-title":"Bispecific antibodies: advancing precision oncology","volume":"10","author":"Herrera","year":"2024","journal-title":"Trends Cancer"},{"key":"2026081210264188900_ref20","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s11095-018-2554-7","article-title":"Pharmaceutical development of AAV-based gene therapy products for the eye","volume":"36","author":"Rodrigues","year":"2019","journal-title":"Pharm Res"},{"key":"2026081210264188900_ref21","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1167\/iovs.64.7.39","article-title":"Gene therapy for retinal degenerative diseases: progress, challenges, and future directions","volume":"64","author":"Drag","year":"2023","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2026081210264188900_ref22","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"2026081210264188900_ref23","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.canlet.2014.10.045","article-title":"Adeno-associated virus-mediated cancer gene therapy: current status","volume":"356","author":"Luo","year":"2015","journal-title":"Cancer Lett"},{"key":"2026081210264188900_ref24","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s40259-018-0295-0","article-title":"Subcutaneous administration of biotherapeutics: an overview of current challenges and opportunities","volume":"32","author":"Bittner","year":"2018","journal-title":"BioDrugs"},{"key":"2026081210264188900_ref25","doi-asserted-by":"publisher","first-page":"103877","DOI":"10.1016\/j.xphs.2025.103877","article-title":"Current and emerging strategies for subcutaneous delivery of high-concentration and high-dose antibody therapeutics","volume":"114","author":"Ren","year":"2025","journal-title":"J Pharm Sci"},{"key":"2026081210264188900_ref26","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1093\/abt\/tbad022","article-title":"Effects of arginine in therapeutic protein formulations: a decade review and perspectives","volume":"6","author":"Ren","year":"2023","journal-title":"Antib Ther"},{"key":"2026081210264188900_ref27","first-page":"2398","article-title":"The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and meta-analysis","volume":"33","author":"Gartlehner","year":"2006","journal-title":"J Rheumatol"},{"key":"2026081210264188900_ref28","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1186\/ar996","article-title":"Does route of administration affect the outcome of TNF antagonist therapy?","volume":"6","author":"Schwartzman","year":"2004","journal-title":"Arthritis Res Ther"},{"key":"2026081210264188900_ref29","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.anai.2017.11.002","article-title":"Home-based subcutaneous immunoglobulin therapy vs hospital-based intravenous immunoglobulin therapy: a prospective economic analysis","volume":"120","author":"Fu","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2026081210264188900_ref30","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1007\/s10875-012-9720-1","article-title":"Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta-analysis","volume":"32","author":"Abolhassani","year":"2012","journal-title":"J Clin Immunol"},{"key":"2026081210264188900_ref31","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2024.2402713","article-title":"Navigating large-volume subcutaneous injections of biopharmaceuticals: a systematic review of clinical pipelines and approved products","volume":"16","author":"Green","year":"2024","journal-title":"mAbs."},{"key":"2026081210264188900_ref32","article-title":"The rise of large-volume subcutaneous administration of biopharmaceuticals, and delivery implications","volume":"10","author":"Schneider","year":"2025","journal-title":"OnDrugDelivery."},{"key":"2026081210264188900_ref33","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s40271-014-0075-y","article-title":"Intravenous versus subcutaneous drug administration. Which do patients prefer? A systematic review","volume":"8","author":"Stoner","year":"2014","journal-title":"Patient"},{"key":"2026081210264188900_ref34","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.jaci.2004.06.053","article-title":"Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home","volume":"114","author":"Gardulf","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"2026081210264188900_ref35","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10875-006-8905-x","article-title":"Health-related quality of life and treatment satisfaction in North American patients with primary immunodeficiency diseases receiving subcutaneous IgG self-infusions at home","volume":"26","author":"Nicolay","year":"2006","journal-title":"J Clin Immunol"},{"key":"2026081210264188900_ref36","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1177\/2374373518770811","article-title":"Preference for subcutaneous injection or intravenous infusion of biological therapy among Italian patients with SLE","volume":"6","author":"Falanga","year":"2019","journal-title":"J Patient Exp"},{"key":"2026081210264188900_ref37","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.jconrel.2020.08.013","article-title":"Advancements in the co-formulation of biologic therapeutics","volume":"327","author":"Chauhan","year":"2020","journal-title":"J Control Release"},{"key":"2026081210264188900_ref38","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1111\/jphp.12731","article-title":"Challenges for the pharmaceutical technical development of protein coformulations","volume":"70","author":"Mueller","year":"2018","journal-title":"J Pharm Pharmacol"},{"key":"2026081210264188900_ref39","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2020.1738691","article-title":"Analytical characterization of co-formulated antibodies as combination therapy","volume":"12","author":"Kim","year":"2020","journal-title":"mAbs."},{"key":"2026081210264188900_ref40","article-title":"Analytical strategies for fixed-dose co-formulated protein therapeutics","author":"Svitel","year":"2019","journal-title":"BioProcess Int"},{"key":"2026081210264188900_ref41","doi-asserted-by":"publisher","first-page":"105073","DOI":"10.1016\/j.ejps.2019.105073","article-title":"Overcoming challenges in co-formulation of proteins with contradicting stability profiles\u2014EPO plus G-CSF","volume":"141","author":"Krieg","year":"2020","journal-title":"Eur J Pharm Sci"},{"key":"2026081210264188900_ref42","doi-asserted-by":"publisher","first-page":"21129","DOI":"10.1038\/s41598-020-77989-w","article-title":"Stability enhancement in a mAb and Fab coformulation","volume":"10","author":"Zhang","year":"2020","journal-title":"Sci Rep"},{"key":"2026081210264188900_ref43","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1093\/abt\/tbad014.018","article-title":"Antibody co-formulation toolbox and capabilities established in WuXi Biologics","volume":"6","author":"Liu","year":"2023","journal-title":"Antib Ther"},{"key":"2026081210264188900_ref44","doi-asserted-by":"publisher","first-page":"3032","DOI":"10.1016\/j.xphs.2018.08.012","article-title":"Coformulation of broadly neutralizing antibodies 3BNC117 and PGT121: analytical challenges during preformulation characterization and storage stability studies","volume":"107","author":"Patel","year":"2018","journal-title":"J Pharm Sci"},{"key":"2026081210264188900_ref45","doi-asserted-by":"publisher","first-page":"4620","DOI":"10.3390\/cancers13184620","article-title":"Improving biologics' effectiveness in clinical oncology: from the combination of two monoclonal antibodies to oligoclonal antibody mixtures","volume":"13","author":"Larbouret","year":"2021","journal-title":"Cancers"},{"key":"2026081210264188900_ref46","author":"US FDA"},{"key":"2026081210264188900_ref47","author":"\u201cCONTRAVE \u2013 New Obesity Medication Now Available\u201d"},{"key":"2026081210264188900_ref48","author":"US FDA","year":"2023"},{"key":"2026081210264188900_ref49","author":"Lilly"},{"key":"2026081210264188900_ref50","author":"Regeneron"},{"key":"2026081210264188900_ref51","author":"Bristol Myers Squibb"},{"key":"2026081210264188900_ref52","author":"Roche"},{"key":"2026081210264188900_ref53","author":"Merck"},{"key":"2026081210264188900_ref54","volume-title":"Guidance for Industry: Codevelopment of Two or more New Investigational Drugs for Use in Combination","author":"US FDA","year":"2013"},{"key":"2026081210264188900_ref55","volume-title":"Guideline on Clinical Development of Fixed Combination Medicinal Products","author":"European Medicines Agency (EMA)","year":"2017"},{"key":"2026081210264188900_ref56","author":"US FDA","year":"2014"},{"key":"2026081210264188900_ref57","author":"US FDA","year":"2019"},{"key":"2026081210264188900_ref58","volume-title":"Guideline on Immunogenicity Assessment of Therapeutic Proteins\u2014Revision 1","author":"European Medicines Agency"},{"key":"2026081210264188900_ref59","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1208\/s12248-014-9599-2","article-title":"Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides\u2014harmonized terminology and tactical recommendations","volume":"16","author":"Shankar","year":"2014","journal-title":"AAPS J"},{"key":"2026081210264188900_ref60","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/cpt.2919","article-title":"Optimizing the dosing regimen of cetuximab and ramucirumab using the model-informed drug development paradigm","volume":"114","author":"Ni","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"2026081210264188900_ref61","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1002\/cpt.1457","article-title":"The US Food and Drug Administration's model-informed drug development paired meeting pilot program: early experience and impact","volume":"106","author":"Madabushi","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"2026081210264188900_ref62","first-page":"625","article-title":"Application of model-informed drug development for combination biologic products: a regulatory perspective","volume":"115","author":"Madabushi","year":"2024","journal-title":"Clin Pharmacol Ther"},{"key":"2026081210264188900_ref63","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1002\/cpt.1363","article-title":"Model-informed drug development: current US regulatory practice and future considerations","volume":"105","author":"Wang","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"2026081210264188900_ref64","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1080\/19420862.2017.1338222","article-title":"Characterization of highly concentrated antibody solution\u2014a toolbox for the description of protein long-term solution stability","volume":"9","author":"Schermeyer","year":"2017","journal-title":"mAbs."},{"key":"2026081210264188900_ref65","doi-asserted-by":"publisher","first-page":"3496","DOI":"10.1016\/j.xphs.2016.08.020","article-title":"Both reversible self-association and structural changes underpin molecular viscoelasticity of mAb solutions","volume":"105","author":"Sarangapani","year":"2016","journal-title":"J Pharm Sci"},{"key":"2026081210264188900_ref66","doi-asserted-by":"publisher","first-page":"4775","DOI":"10.1021\/acs.molpharmaceut.9b00430","article-title":"Determination of protein\u2013protein interactions in a mixture of two monoclonal antibodies","volume":"16","author":"Singh","year":"2019","journal-title":"Mol Pharm"},{"key":"2026081210264188900_ref67","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2024.2339582","article-title":"Antibody association in solution: cluster distributions and mechanisms","volume":"16","author":"Brudar","year":"2024","journal-title":"mAbs."},{"key":"2026081210264188900_ref68","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.xphs.2018.07.007","article-title":"How well do low- and high-concentration protein interactions predict solution viscosities of monoclonal antibodies?","volume":"108","author":"Woldeyes","year":"2019","journal-title":"J Pharm Sci"},{"key":"2026081210264188900_ref69","doi-asserted-by":"publisher","first-page":"4098","DOI":"10.1021\/acs.molpharmaceut.2c00534","article-title":"Stability convergence in antibody coformulations","volume":"19","author":"Zhang","year":"2022","journal-title":"Mol Pharm"},{"key":"2026081210264188900_ref70","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s11095-016-2055-5","article-title":"Contrasting the influence of cationic amino acids on the viscosity and stability of a highly concentrated monoclonal antibody","volume":"34","author":"Dear","year":"2017","journal-title":"Pharm Res"},{"key":"2026081210264188900_ref71","doi-asserted-by":"publisher","first-page":"11225","DOI":"10.1021\/acs.iecr.6b02042","article-title":"Viscosity reduction of a concentrated monoclonal antibody with arginine\u00b7HCl and arginine\u00b7glutamate","volume":"55","author":"Borwankar","year":"2016","journal-title":"Ind Eng Chem Res"},{"key":"2026081210264188900_ref72","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2026.115885","article-title":"High dose subcutaneous Administration of Biologics: overcoming barriers through formulation and device innovation","volume":"235","author":"Khan","year":"2024","journal-title":"Adv Drug Deliv Rev"},{"key":"2026081210264188900_ref73","author":"Ypsomed"},{"key":"2026081210264188900_ref74","author":"SHL Medical"},{"key":"2026081210264188900_ref75","author":"Ypsomed"},{"key":"2026081210264188900_ref76","author":"West Pharma"},{"key":"2026081210264188900_ref77","author":"Vetter Pharma"},{"key":"2026081210264188900_ref78","author":"Vetter Pharma"},{"key":"2026081210264188900_ref79","author":"Kaleo"},{"key":"2026081210264188900_ref80","author":"Kaleo.","year":"2024"},{"key":"2026081210264188900_ref81","author":"Ypsomed"},{"key":"2026081210264188900_ref82","author":"Ypsomed"},{"key":"2026081210264188900_ref83","author":"Ypsomed","year":"2014"},{"key":"2026081210264188900_ref84","author":"Drug Development & Delivery"},{"key":"2026081210264188900_ref85","author":"Credence MedSystems"},{"key":"2026081210264188900_ref86","first-page":"110","author":"Bryllan & Credence MedSystems","year":"2023"},{"key":"2026081210264188900_ref87","author":"WindGap Medical"},{"key":"2026081210264188900_ref88","article-title":"Beyond The Barrel: A Dual-Cartridge Improvement To Traditional Dual-Chamber Devices","author":"Buchine","year":"2025","journal-title":"ONdrugDelivery."},{"key":"2026081210264188900_ref89","author":"Debiotech"},{"key":"2026081210264188900_ref90","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1080\/03091902.2021.1936239","article-title":"Large-volume subcutaneous drug delivery: a review of current challenges and emerging solutions for viscous and high-dose biologics","volume":"45","author":"Patel","year":"2021","journal-title":"J Med Eng Technol"},{"key":"2026081210264188900_ref91","article-title":"Delivering Complexity: Device Considerations for Two-Component Injectable Formulations","author":"Balson","year":"2025","journal-title":"ONdrugDelivery."},{"key":"2026081210264188900_ref92","author":"European Medicines Agency, PRAC","year":"2020"},{"key":"2026081210264188900_ref93","doi-asserted-by":"publisher","first-page":"508","DOI":"10.5731\/pdajpst.2015.006387","article-title":"Testing of container closure systems for prefillable syringes with respect to container closure integrity","volume":"70","author":"Werk","year":"2016","journal-title":"PDA J Pharm Sci Technol"},{"key":"2026081210264188900_ref94","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1080\/17425247.2019.1682995","article-title":"Clinical considerations and strategies for large-volume subcutaneous drug delivery","volume":"16","author":"Patel","year":"2019","journal-title":"Expert Opin Drug Deliv"},{"key":"2026081210264188900_ref95","first-page":"1473","article-title":"Device design and human factors considerations for large-volume subcutaneous injection","volume":"18","author":"Adjectey","year":"2021","journal-title":"Expert Opin Drug Deliv"},{"key":"2026081210264188900_ref96","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1021\/acs.analchem.2c03099","article-title":"Identification of hetero-aggregates in antibody co-formulations by multi-dimensional liquid chromatography coupled to mass spectrometry","volume":"95","author":"Kuhne","year":"2023","journal-title":"Anal Chem"},{"key":"2026081210264188900_ref97","first-page":"2514879","article-title":"Advanced functional materials for intelligent drug delivery systems in combination biologics","volume":"35","author":"Coates","year":"2025","journal-title":"Adv Funct Mater"},{"key":"2026081210264188900_ref98","doi-asserted-by":"publisher","first-page":"064125","DOI":"10.1063\/1.5127778","article-title":"A 3D-printed microfluidic-enabled hollow microneedle architecture for transdermal drug delivery","volume":"13","author":"Yeung","year":"2019","journal-title":"Biomicrofluidics."},{"key":"2026081210264188900_ref99","doi-asserted-by":"publisher","first-page":"6191","DOI":"10.1039\/D4LC00864B","article-title":"Microfluidic integration for advanced drug co-delivery and monitoring in combination biologic therapies","volume":"25","author":"Park","year":"2025","journal-title":"Lab Chip"}],"container-title":["Antibody Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/abt\/advance-article-pdf\/doi\/10.1093\/abt\/tbag034\/68568173\/tbag034.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/abt\/article-pdf\/9\/3\/437\/68568173\/tbag034.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/abt\/article-pdf\/9\/3\/437\/68568173\/tbag034.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T14:28:07Z","timestamp":1786544887000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/abt\/article\/9\/3\/437\/8712859"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":99,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6,29]]}},"URL":"https:\/\/doi.org\/10.1093\/abt\/tbag034","relation":{},"ISSN":["2516-4236"],"issn-type":[{"value":"2516-4236","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,6,22]]}}}